Summary: AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie’s financials
Summary: AbbVie has agreed to acquire ImmunoGen for $10 billion, nearly double its previous trading
Summary: AbbVie has agreed to acquire ImmunoGen in a $10.1 billion all-cash deal, aiming to
Summary: AbbVie agreed to acquire biotech company ImmunoGen for $10.1 billion in an all-cash transaction,
Summary: AbbVie is set to acquire ImmunoGen for $10.1 billion, gaining Elahere, a promising ovarian
Summary: AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying
Summary: A proven track record of putting shareholders first is part of the litmus test
Summary: AbbVie Inc.’s revenue growth has turned negative due to the expiration of Humira patents,
Summary: Despite his reputation as a growth investor, Peter Lynch offers valuable insights into dividend
Summary: AbbVie’s management increased the financial guidance for its 2023 adjusted diluted EPS from $10.86–$11.06